A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal

@article{Rindi2018ACC,
  title={A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal},
  author={Guido Rindi and David S. Klimstra and Behnoush Abedi-Ardekani and Sylvia L. Asa and F T Bosman and Elisabeth Brambilla and Klaus J. Busam and Ronald R. de Krijger and Manfred Dietel and Adel K. El‐Naggar and Lynnette Fernandez-Cuesta and G{\"u}nter Kl{\"o}ppel and W Glenn McCluggage and Holger Moch and Hiroko Ohgaki and Emad A. Rakha and Nicholas Simon Reed and Brian Rous and Hironobu Sasano and Aldo Scarpa and Jean-Yves Scoazec and William D. Travis and Giovanni Tallini and Jacqueline Trouillas and J Han Jm van Krieken and Ian A. Cree},
  journal={Modern Pathology},
  year={2018},
  volume={31},
  pages={1770 - 1786}
}
The classification of neuroendocrine neoplasms (NENs) differs between organ systems and currently causes considerable confusion. A uniform classification framework for NENs at any anatomical location may reduce inconsistencies and contradictions among the various systems currently in use. The classification suggested here is intended to allow pathologists and clinicians to manage their patients with NENs consistently, while acknowledging organ-specific differences in classification criteria… Expand
Validation of prognostic significance of the proposed uniform classification framework in neuroendocrine neoplasms of the breast
TLDR
The universal classification framework for NEN allowed us to further refine the breast carcinoma with neuroendocrine differentiation as a unique pathologic and clinical entity, which has worse clinical outcome compared to IDC-NST. Expand
Neuroendocrine neoplasms of the breast: A review focused on the updated World Health Organization (WHO) 5th Edition morphologic classification
TLDR
This review will provide an update to the current WHO classification of neuroendocrine breast neoplasms and describe pertinent clinical, histologic, and molecular features of these uncommon tumors. Expand
Skin Neuroendocrine Neoplasms
TLDR
A realistic and practical formulation for skin NENs based on clinico-pathological and molecular data is presented with the goal to manage these tumors in the most uniform way possible. Expand
Correlation of World Health Organization 2010 Classification for Gastroenteropancreatic Neuroendocrine Neoplasms with the Prognosis of Ovarian Neuroendocrine Neoplasms: Kansai Clinical Oncology Group-Protocol Review Committee/Intergroup Study
TLDR
Retrospective adaption of GEP-N EN classification to O-NENs is feasible and correlates well with the prognosis of O- NENs, and this classification could be introduced for ovarian tumors. Expand
Neuroendocrine neoplasms of the lung: a pathology update
Neuroendocrine tumors and neuroendocrine carcinomas in the lung are distinct and separate entities featuring neuroendocrine differentiation, for which an accurate classification is clinicallyExpand
Update on Histological Reporting Changes in Neuroendocrine Neoplasms
TLDR
The heterogeneity of NEN regarding the organ of origin, differentiation and molecular subtypes make development of personalised therapy a challenge needing more international and interdisciplinary collaborations and clinical trials allowing stratification according to biological subgroups. Expand
Morphologic and molecular classification of lung neuroendocrine neoplasms
TLDR
Lights and shadows of the current classification of lung NENs are emphasized and an alternative outlook on these tumors focused on what the authors currently know about the biological determinants and the natural history of disease is provided. Expand
Pancreatic neuroendocrine neoplasms: current state and ongoing controversies on terminology, classification and prognostication.
TLDR
Neuroendocrine neoplasms with well differentiated morphology but Ki-67 >20% are now regarded as PanNET Grade 3 (G3); they have been shown to have a prognosis significantly worse than lesser grade PanNETs but still incomparably better than frank PDNECs, the latter typically has Ki- 67 >50% and require platinum-based chemotherapy. Expand
Introduction to neuroendocrine neoplasms of the digestive system: definition and classification
TLDR
Neoplasms characterized by the expression of markers of Neuroendocrine differentiation in neoplastic cells are defined neuroendocrine, which comprises tumors found at different sites of the body with similar morphology but different behavior and genetic background. Expand
Pancreatic neuroendocrine tumors G3 and pancreatic neuroendocrine carcinomas: Differences in basic biology and treatment
TLDR
The relevant literature is summarized from the perspective of the differences between pNETs G3 and pNECs in order to deepen understanding of these diseases and discuss future research directions. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 123 REFERENCES
Pathology Reporting of Neuroendocrine Tumors: Application of the Delphic Consensus Process to the Development of a Minimum Pathology Data Set
TLDR
Although there remains disagreement among experts about the specific classification system thatshould be used, there is agreement about the fundamental pathology data that should be reported. Expand
Grading the neuroendocrine tumors of the lung: an evidence-based proposal.
TLDR
A three-tiers grading system based on Ki67 index, mitotic count, and necrosis with cutoffs specifically generated for lung neuroendocrine tumors is prognostically effective and accurate. Expand
Neuroendocrine Neoplasms: Dichotomy, Origin and Classifications
TLDR
Comparison of the WHO classification of digestive system NENs with other NEN classifications reveals site-specific differences in terminology and a general lack of grading systems, but all classifications recognize the existence of the two major NEN families and provide a general basis for their prognostic and therapeutic stratification. Expand
Cyto-histology in NET: what is necessary today and what is the future?
TLDR
The carcinoid as originally described is part of the relatively large family of neuroendocrine neoplasia found in almost every organ, and aggressive features with extensive necrosis, severe atypia and abundant, atypical mitoses for high grade cancer types. Expand
Ki-67 Antigen in Lung Neuroendocrine Tumors: Unraveling a Role in Clinical Practice
TLDR
The conclusion is that Ki-67 is a feasible and potentially meaningful marker in lung NE tumors, but more data are needed to determine its ideal function in this setting of tumors. Expand
Well‐differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high‐grade (G3) cases
TLDR
This review examines the current concepts and issues of nomenclature and grading of PanNETs and PanNECs and discusses an integrative and practical diagnostic approach to aid in discriminating challenging cases. Expand
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.
  • M. Caplin, E. Baudin, +8 authors W. Travis
  • Medicine
  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2015
TLDR
PCs are complex tumors which require a multidisciplinary approach and long-term follow-up, and may be considered as first-line systemic antiproliferative treatment in unresectable PCs, particularly of low-grade TC and AC. Expand
Poorly Differentiated Neuroendocrine Carcinomas of the Pancreas: A Clinicopathologic Analysis of 44 Cases
TLDR
Poorly differentiated neuroendocrine carcinoma of the pancreas is a highly aggressive neoplasm, with frequent metastases and poor survival, emphasizing that diagnostic criteria need to be clearly followed to ensure accurate diagnosis. Expand
Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas
TLDR
Mixed grades can occur in WD-NETs, which are distinguished from PD-NECs by their unique phenotype, proliferative indices, and the genotype, and this phenomenon of mixed grade provides additional evidence to the growing recognition that the current WHO G3 category contains both WD- NETs as well as PD-Ns. Expand
Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation
TLDR
The article highlights “prostate carcinoma with overlapping features of small cell carcinoma and acinar adenocarcinoma” and “castrate-resistant prostate cancer with small cell cancer-like clinical presentation”. Expand
...
1
2
3
4
5
...